AREV Life Sciences Global Corp.
AREV
CNSX
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 77.59% | 56.57% | -13.62% | -42.06% | 49.76% |
| Total Depreciation and Amortization | -49.86% | -38.45% | -26.80% | -17.28% | -11.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.99% | 63.05% | 167.72% | 178.62% | -128.87% |
| Change in Net Operating Assets | -79.64% | -54.50% | 825.31% | 317.42% | 409.24% |
| Cash from Operations | 62.01% | 70.15% | 87.42% | 81.10% | 67.32% |
| Capital Expenditure | 129.03% | 129.03% | 98.40% | -124.49% | 77.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -188.77% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.72% | 52.36% | 76.51% | 76.51% | 89.78% |
| Cash from Investing | 99.73% | 99.73% | 97.57% | -352.11% | -339.19% |
| Total Debt Issued | -67.10% | -63.36% | -89.63% | -98.28% | -- |
| Total Debt Repaid | -- | -110.10% | -107.62% | -- | 156.51% |
| Issuance of Common Stock | -92.54% | -92.54% | -41.55% | -80.23% | -60.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -84.99% | -85.58% | -81.95% | -87.66% | -4.49% |
| Foreign Exchange rate Adjustments | 100.00% | -- | -- | -- | -200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -8.70% | 95.33% | 102.74% | 0.72% | 34.75% |
